Previous 10 | Next 10 |
home / stock / hls:cc / hls:cc news
HLS Therapeutics Announces Q4 and Fiscal 2022 Financial Results Canada NewsWire TORONTO , March 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular...
HLS Therapeutics to Host Q4 and Fiscal 2022 Financial Results Conference Call Canada NewsWire TORONTO , March 2, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and Fiscal 2022 financial results on T...
Healthcare stocks aren’t attractive to investors in 2022. The selloff is more severe than information technology, given the sector’s year-to-date loss of nearly 51%. Moreover, underperforming cannabis stocks like Canopy Growth , Tilray , and Cronos Group are among th...
HLS Therapeutics Announces Board Appointment Canada NewsWire TORONTO , Nov. 29, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces ...
HLS Therapeutics to Present at the Stifel Healthcare Conference Canada NewsWire TORONTO , Nov. 14, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular market...
HLS Therapeutics Announces Q3 Fiscal 2022 Financial Results and Renewal of Normal Course Issuer Bid Canada NewsWire Q3 2022 revenue of $15.7 million , Adjusted EBITDA of $6.0 million and cash from operations of $4.2 million . Total Vascepa prescri...
HLS Therapeutics Highlights Key Data on the Late Breaking RESPECT-EPA Study Presented at the American Heart Association Canada NewsWire Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore Cardiovascular Risk Reduction Benefits of Eicosapentaen...
HLS Therapeutics to Host Q3 Fiscal 2022 Financial Results Conference Call Canada NewsWire TORONTO , Oct. 27, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2022 financial results o...
HLS Therapeutics Announces Updates to its Credit Agreement Canada NewsWire TORONTO , Oct. 3, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, an...
The S&P/TSX Composite Index was down 234 points in late-morning trading on Friday, September 16. This would represent the third triple-digit decline over this trading week. Some of the worst-performing sectors included health care, information technology, and industrials. Today,...
News, Short Squeeze, Breakout and More Instantly...
HLS Therapeutics Inc. Company Name:
HLS:CC Stock Symbol:
TSXC Market:
HLS Therapeutics Inc. Website:
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust Canada NewsWire Total consideration of up to $45.75 million , which consists of upfront cash, sales-based milestone payments and DRI Healthcare's assumption of future mi...
A look at the top 10 most actives in Canada BlackBerry Limited (BB) rose 10.5% to $3.36 on volume of 12,209,225 shares Solstice Gold Corp. (SGC) fell 33.3% to $0.02 on volume of 11,588,936 shares HIGH INTEREST SAVINGS ACCOUNT FUND (HISA) fell 0.3% to $50.01 on volume of 10,628,355 shares ...
Gold Springs Resource Corp. (GRC:CA) is expected to report for Q1 2024 Primo Water Corporation (PRMW:CA) is expected to report $0.18 for Q1 2024 Greenlane Renewables Inc. (GRN:CA) is expected to report $-0.01 for Q1 2024 Kelso Technologies Inc. (KLS:CA) is expected to report for Q1 20...